Keybanc Analyst Initiates Coverage on ResMed with Overweight Rating and Revised Price Target
On February 6, 2024, Brett Fishbin, an esteemed analyst at Keybanc, made a noteworthy move by initiating coverage on ResMed ...
Tag: RMD
Mizuho Analyst Raises Price Target for ResMed Expresses Bullish Sentiment
On January 30, 2024, Mizuho analyst Anthony Petrone expressed his bullish sentiment towards ResMed (NYSE: RMD) by maintaining a Buy ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
